<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00825344</url>
  </required_header>
  <id_info>
    <org_study_id>WU08-6987</org_study_id>
    <nct_id>NCT00825344</nct_id>
  </id_info>
  <brief_title>Preoperative Etanercept Before Inguinal Hernia Surgery</brief_title>
  <official_title>A Randomized Controlled Study Evaluating Pre-operative Etanercept on the Severity of Postoperative Pain After Inguinal Hernia Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Walter Reed Army Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>John P. Murtha Neuroscience and Pain Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inguinal hernia repair is one of the most frequently performed operations in young men.
      Persistent pain after inguinal surgery represents a significant cause of disability,
      occurring in between 15%-35% of cases. In a majority of these patients, their groin pain
      persisted after a previous hernia repair. The main type of chronic postsurgical pain is
      neuropathic, caused by injured nerves. One of the principal components in the pathophysiology
      of postsurgical pain is cytokines, specifically tumor necrosis factor (TNF). In animal
      studies, injecting TNF inhibitors before nerve injury can reduce pain behaviors and
      neuropathology. Finding a way to reduce the incidence of postsurgical pain after hernia
      repair could enhance function, and reduce the need for opioids and other analgesics. The
      investigators intend to conduct the first randomized, controlled study evaluating whether
      preemptive administration of a tumor necrosis inhibitor can reduce postoperative pain and
      opioid consumption after hernia repair. This is important because the degree and intensity of
      postsurgical pain is a major predictor for the development of chronic postsurgical pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      76 patients with an inguinal hernia scheduled for surgical repair will be randomized in a 1:1
      ratio to receive either subcutaneous etanercept or saline before skin incision. The study
      will be double-blind (i.e. neither the surgeon, anesthesiologist, nor the person
      administering the injection will know which group they were assigned to). Group I will
      receive 50 mg of subcutaneous etanercept mixed in 1 ml sterile water 90-120&quot; before skin
      incision. Group II will receive 1 ml of sterile water 90-120&quot; before skin incision. The
      anesthesia and surgical procedures will be standardized. For the next 24 hours, patients will
      keep a q4 hour pain diary recording their average pain on a 0-10 numerical rating scale. They
      will also record the number of Percocet tablets they took. All patients will be seen 1 month
      after their surgery, where their average pain score, work status, and analgesic intake (if
      any) will be recorded. Patients will then be followed with a telephone follow-up 3, 6 and
      12-months post-procedure, where the same variables will be recorded.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numerical Rating Scale Pain Score</measure>
    <time_frame>24 hours</time_frame>
    <description>0-10 pain score through 24-hours post-surgery. 0 is no pain and 10 is the worse pain imaginable. The primary outcome reported measure is the average of 4 scores, each comprised of 6-hour time intervals during the 24hour period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analgesic Usage</measure>
    <time_frame>24 hours</time_frame>
    <description>Number of oxycodone/ acetaminophen tablets consumed through 24 hours post-surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Post-surgical Pain</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Patients with persistent post-surgical pain</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Inguinal Hernia</condition>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Etanercept 50 mg preoperatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subcutaneous saline preoperatively</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>50 mg subcutaenous preoperatively</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Given subcutaneously preoperatively</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Demonstrable hernia evident using ultrasound, computed tomography, or on physical
             exam.

          2. Pt scheduled for unilateral inguinal hernia repair.

          3. Symptoms present for &lt; 6 months.

        Exclusion Criteria:

          1. Non-elective surgery.

          2. Previous hernia repair at the same site, or surgery near the site of the hernia.

          3. Demyelinating neurological disease.

          4. Current or recent (&lt; 6 years) history of substance abuse.

          5. Pregnancy, which will be ruled out by a urine pregnancy test in women of childbearing
             age.

          6. Pre-existing untreated psychiatric condition that could preclude an optimal treatment
             response (e.g. untreated posttraumatic stress disorder).

          7. Unstable medical condition (e.g. unstable angina or congestive heart failure or
             severe).

          8. Rheumatoid arthritis, or other systemic conditions that might respond to TNF
             inhibitors.

          9. Pt is immunosuppressed or is taking other drugs (e.g. corticosteroids) that might
             suppress the immune system.

         10. Systemic infection.

         11. Any opioid analgesics within 48 hours of skin incision.

         12. Any use of tricyclic antidepressants, serotoninin-norepinephrine reuptake inhibitors,
             or anticonvulsants within 72 hours of skin incision.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Rehrig, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Walter Reed Army Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Walter Reed Army Medical Center</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cheek CM, Black NA, Devlin HB, Kingsnorth AN, Taylor RS, Watkin DF. Groin hernia surgery: a systematic review. Ann R Coll Surg Engl. 1998;80 Suppl 1:S1-80.</citation>
    <PMID>11432408</PMID>
  </reference>
  <reference>
    <citation>Fränneby U, Sandblom G, Nordin P, Nyrén O, Gunnarsson U. Risk factors for long-term pain after hernia surgery. Ann Surg. 2006 Aug;244(2):212-9.</citation>
    <PMID>16858183</PMID>
  </reference>
  <reference>
    <citation>Ferzli GS, Edwards E, Al-Khoury G, Hardin R. Postherniorrhaphy groin pain and how to avoid it. Surg Clin North Am. 2008 Feb;88(1):203-16, x-xi. doi: 10.1016/j.suc.2007.10.006. Review.</citation>
    <PMID>18267170</PMID>
  </reference>
  <reference>
    <citation>Sommer C, Kress M. Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett. 2004 May 6;361(1-3):184-7. Review.</citation>
    <PMID>15135924</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2009</study_first_submitted>
  <study_first_submitted_qc>January 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2009</study_first_posted>
  <results_first_submitted>April 12, 2013</results_first_submitted>
  <results_first_submitted_qc>October 24, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 13, 2013</results_first_posted>
  <last_update_submitted>September 6, 2017</last_update_submitted>
  <last_update_submitted_qc>September 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>postoperative pain</keyword>
  <keyword>inguinal hernia</keyword>
  <keyword>chronic postsurgical pain</keyword>
  <keyword>cytokine</keyword>
  <keyword>preemptive analgesia</keyword>
  <keyword>patients with inguinal hernia scheduled for surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Hernia</mesh_term>
    <mesh_term>Hernia, Inguinal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Etanercept</title>
          <description>Etanercept 50 mg preoperatively
Etanercept : 50 mg subcutaenous preoperatively</description>
        </group>
        <group group_id="P2">
          <title>Saline</title>
          <description>Subcutaneous saline preoperatively
Saline : Given subcutaneously preoperatively</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>Etanercept 50 mg preoperatively
Etanercept : 50 mg subcutaenous preoperatively</description>
        </group>
        <group group_id="B2">
          <title>Group 2</title>
          <description>Subcutaneous saline preoperatively
Saline : Given subcutaneously preoperatively</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="77"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.4" spread="3.1"/>
                    <measurement group_id="B2" value="58.4" spread="2.8"/>
                    <measurement group_id="B3" value="57.9" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Numerical Rating Scale Pain Score</title>
        <description>0-10 pain score through 24-hours post-surgery. 0 is no pain and 10 is the worse pain imaginable. The primary outcome reported measure is the average of 4 scores, each comprised of 6-hour time intervals during the 24hour period.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Etanercept 50 mg preoperatively
Etanercept : 50 mg subcutaenous preoperatively</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Subcutaneous saline preoperatively
Saline : Given subcutaneously preoperatively</description>
          </group>
        </group_list>
        <measure>
          <title>Numerical Rating Scale Pain Score</title>
          <description>0-10 pain score through 24-hours post-surgery. 0 is no pain and 10 is the worse pain imaginable. The primary outcome reported measure is the average of 4 scores, each comprised of 6-hour time intervals during the 24hour period.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="1.9"/>
                    <measurement group_id="O2" value="3.9" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Analgesic Usage</title>
        <description>Number of oxycodone/ acetaminophen tablets consumed through 24 hours post-surgery</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Etanercept 50 mg preoperatively
Etanercept : 50 mg subcutaenous preoperatively</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Subcutaneous saline preoperatively
Saline : Given subcutaneously preoperatively</description>
          </group>
        </group_list>
        <measure>
          <title>Analgesic Usage</title>
          <description>Number of oxycodone/ acetaminophen tablets consumed through 24 hours post-surgery</description>
          <units>tablets</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="2.8"/>
                    <measurement group_id="O2" value="5.8" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chronic Post-surgical Pain</title>
        <description>Patients with persistent post-surgical pain</description>
        <time_frame>Up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Etanercept 50 mg preoperatively
Etanercept : 50 mg subcutaenous preoperatively</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Subcutaneous saline preoperatively
Saline : Given subcutaneously preoperatively</description>
          </group>
        </group_list>
        <measure>
          <title>Chronic Post-surgical Pain</title>
          <description>Patients with persistent post-surgical pain</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>Etanercept 50 mg preoperatively
Etanercept : 50 mg subcutaenous preoperatively</description>
        </group>
        <group group_id="E2">
          <title>Group 2</title>
          <description>Subcutaneous saline preoperatively
Saline : Given subcutaneously preoperatively</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Only one type of surgery studied; more males than females enrolled (function of military treatment facility and type of population)</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Steven P. Cohen</name_or_title>
      <organization>Johns Hopkins</organization>
      <phone>410-955-1818</phone>
      <email>scohen40@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

